These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 28720318)
1. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model. Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318 [TBL] [Abstract][Full Text] [Related]
2. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model. Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model. Kang KR; Huh DH; Kim JA; Kang JH BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798 [TBL] [Abstract][Full Text] [Related]
4. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A; Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665 [TBL] [Abstract][Full Text] [Related]
5. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365 [TBL] [Abstract][Full Text] [Related]
6. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491 [TBL] [Abstract][Full Text] [Related]
8. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory. Stenger RM; Smits M; Kuipers B; van Gaans-van den Brink J; Poelen M; Boog CJ; van Els CA Vaccine; 2010 Sep; 28(40):6637-46. PubMed ID: 20637762 [TBL] [Abstract][Full Text] [Related]
9. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants. Simondon F; Yam A; Gagnepain JY; Wassilak S; Danve B; Cadoz M Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):927-32. PubMed ID: 9031875 [TBL] [Abstract][Full Text] [Related]
10. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938 [TBL] [Abstract][Full Text] [Related]
11. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection. Patel SS; Wagstaff AJ Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742 [TBL] [Abstract][Full Text] [Related]
12. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates. Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641 [TBL] [Abstract][Full Text] [Related]
13. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554 [TBL] [Abstract][Full Text] [Related]
15. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection. Matheson AJ; Goa KL Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466 [TBL] [Abstract][Full Text] [Related]
16. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Cherry JD; Gornbein J; Heininger U; Stehr K Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041 [TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Afari EA; Kamiya Y; Nkrumah FK; Dunyo SK; Akpedonu P; Kamiya H; Fukai F Ann Trop Paediatr; 1996 Mar; 16(1):39-48. PubMed ID: 8787364 [TBL] [Abstract][Full Text] [Related]
19. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976 [TBL] [Abstract][Full Text] [Related]
20. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Tapiainen T; Cherry JD; Heininger U Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]